“Penny stocks” don’t have a formal EU definition, but many investors use the shorthand for shares trading below €1.00. On Frankfurt, that tier is a mixed bag: tiny caps, thin liquidity, and wide spreads—but also genuine businesses that slipped out of favor. Below are five sub-€1 names currently trading in Frankfurt, what they do, and the signposts I’d watch next. Use limit orders, do your own homework, and expect volatility.
Mobotix is a German maker of premium IP video systems—“cameras as computers” with on-device analytics—sold into security, industrial and critical-infrastructure use cases. The company positions itself on German engineering and edge-processing rather than commodity hardware. As of early September, MBQ was still trading under €1 on Frankfurt.
What to monitor: order momentum in Europe, gross margin traction (sign of mix improving toward higher-value software/analytics), and any fresh design-wins in verticals like utilities or logistics. If management can convert pipeline to recurring software and services, even modest operating leverage matters at this cap scale.
Best known for legacy directory assistance, 11 88 0 has spent years pushing into digital marketing for German small businesses—think listings, simple sites, leads, and call-center support. The structural question is whether its “Digital” segment can outrun the long fade in directory calls. Recently the shares have traded around the €0.60–€0.70 band on Frankfurt.
What to watch: net adds in digital contracts, churn, and whether cost discipline can stabilize cash flow as the mix tilts online. Any credible disclosure that recurring digital revenue is compounding (even at single digits) tends to re-rate models for companies in this transition bucket.
Formerly CR Capital, CR Energy is an investment holding company that acquires, builds and exits stakes in niche businesses geared to energy efficiency and resource-saving technologies. It’s small, lean (a handful of employees), and—like many holdcos—trades at a perceived “conglomerate discount.” The share price has been hovering beneath €1 in recent sessions.
What I’d track: transparency on net asset value (NAV) and valuation marks, realized exits, and cash returns (buybacks/dividends) versus reinvestment. In micro holdcos, catalysts often come from simplifying the structure or proving that portfolio companies can scale beyond pilot projects.
NAGA runs a fintech brokerage with a social-investing layer—CFDs, stocks, and copy trading—competing in a crowded European market. The equity trades under €1 on Frankfurt and tends to move with headlines on user growth, unit economics, and regulatory milestones.
The strategic narrative is clear enough: scale users, lift ARPU, and convert activity into sustainable profitability. The execution risk is, too: customer acquisition costs, churn, and compliance. For traders, the key tell is whether updates show improving contribution margins alongside steady active-trader cohorts; for investors, watch cash runway and the pace of product integration across platforms.
Bio-Gate develops antimicrobial surface technologies—silver-based coatings like HyProtect™ for medical implants, plus materials and dermacosmetics. It’s a classic micro-innovator: deep in a specialized tech stack, reliant on partnering and regulatory pathways to monetize. The stock remains below €1. For a small med-tech like this, the “what next” is less about quarterly noise and more about milestones: OEM agreements with device makers, clinical/real-world validation that supports uptake, and any signs of scaled production. If one or two anchor partnerships inflect, revenue concentration is a risk—but it’s also the most plausible path to step-change growth.
They’re exchange-listed, but liquidity is still king. Frankfurt/Xetra listings don’t magically cure small-cap frictions: many microcaps print sporadically, and the bid-ask can be unforgiving. Use limit orders, and check the depth before you click. Segment matters, too: companies in the Open Market (Scale/Basic Board) follow different transparency obligations than the Regulated Market (General/Prime Standard). That often explains why disclosure cadence varies name to name.
“Penny” is a price, not a thesis. A sub-€1 quote doesn’t make a stock cheaper in business terms—it might simply mean there are many shares outstanding or that sentiment has compressed the multiple. Focus on revenue quality, balance sheet, and cash conversion, not just the sticker price. (In practice, thinly traded pennies can move fast in both directions, amplifying narrative swings.)
Mobotix: proof that higher-margin software/analytics is gaining share of mix, plus named wins in critical infrastructure.
11 88 0 Solutions: evidence that the Digital segment’s recurring revenue is compounding and offsetting legacy decay.
CR Energy: NAV clarity and cash returns—signals the market loves in small holdcos.
NAGA: sustained growth in active users with improving unit economics and compliance comfort.
Bio-Gate: OEM partnerships and validation around coatings like HyProtect™.
Why bother at all? For some investors, Europe’s smallest names are where re-ratings start: a cleaner balance sheet, one new contract, or a better-than-feared update can move the needle when expectations are minimal. But the reverse is also true—disappointments hit harder when liquidity is thin. Treat position sizing and risk management as features, not footnotes.
Disclosure/Risk note: This feature is for information only and is not investment advice. Small-cap shares can be illiquid and volatile. You may lose all or a substantial portion of your capital. Always do your own research and consult a qualified adviser before investing.